Biotech Hangout

$NVS paying $2bn for Synnovation's SNV4818, after $LLY paid $1.5bn for Scorpion's STX-478. Mechanistically, seems like good news for $RLAY, bad for $OKUR & $COGT

$NVS x Pikavation Therapeutics Novartis will pay $2 billion upfront and up to USD 1 billion in milestone payments to Synnovation Therapeutics, LLC to acquire Pikavation Therapeutics, Inc., a wholly- owned subsidiary of Synnovation that holds a portfolio of pan-mutant selective PI3Kα inhibitor programs, including SNV4818. The transaction is expected to close in H1 2026, subject to the satisfaction or waiver of customary closing conditions, including regulatory approvals.  .

#BiotechHangout is taking a break this week and will return next Friday, March 27. While we’re away, stream the latest episodes on Spotify, Apple Podcasts, YouTube, Amazon Music, and BiotechHangout.com.

Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether the agency will agree to approve them is still unknown. #FDA #pharma #biospace hubs.li/Q047y7g_0

$REPL advancing a bit pm. Guess it's because Cantor's note with a positive tone for approval after meeting with mgmt. They "came away incrementally more positive in the likelihood of approval". I view the reasons for optimism as fairly weak in particular that their sales team is "pumped about a potential launch" and the support from the melanoma community (?). The roles of Prasad and Pazdur in the CRL and the presenced of new team members at the FDA involved in the review remain speculative. I expect another CRL.

@yaireinhorn @ARKInvest @CathieDWood @wintonARK @BiotechCH @bradloncar @TimOpler @Maximus_Holla @BioStocks @Pharmdca This podcast I did with Xaira is very relevant to this: podcasts.apple.com/gb/podcast/van…

I'll be covering this morning's @ChinaSelect hearing on China's ascension in the pharma industry, from APIs to licensing deals. We're underway. Here are the witnesses:

@SarahKarlin @daphnezohar @BiotechCH Well the reality is what was happening at federal agencies while doom and gloom wasn’t necessarily translated to the success many many biotechs were having. So definitely more pieces highlighting scientific success from bios could have been made.

$CTMX $250M offering priced at $5.30/share

$CTMX raise not go well b/c many investor are concern with gr3 diarrhea. 10% gr3 diarrhea is not concern. I am experience >10% incidence of gr3 diarrhea every time I am eat wife cooking.

May be one reason for this $CTMX drop today is the normal tissue expression of target and thus diarrhea . While not many tumor specific antigens defined in colon or GI cancers , there are emerging GI tumor expressed targets such as Adam 9 from $MGNX where co just reported responses in phase 1 only a few months after start.

$OVID $60M PIPE @ $2/share Point72, Adage Capital, ADAR1 Capital, Affinity Asset Advisors, Ally Bridge Group, Balyasny Asset Management, Coastlands Capital, Eventide Asset Management, Janus Henderson, and RA Capital

@Sanctuary_Bio @tallnfat $TERN has a clear 1L CML drug that will make >$3B. Not only is ORR better than Scemblix, the duration of treatment also likely to be much longer.

$ALDX FDA Response Received: Aldeyra Therapeutics, Inc. received a Complete Response Letter from the FDA on March 17, 2026, which indicates their drug reproxalap for dry eye disease did not demonstrate sufficient efficacy in studies. The company has enough funds to maintain operations until 2028, but must address FDA concerns before resubmitting their New Drug Application. stockinsights.ai/us/ALDX/8-K/le…

Sitting ACIP member Robert Malone calls for impeachment of the federal judge in Massachusetts that ruled against the CDC and current committee members.

$BCYC to discontinue the Phase 1/2 Duravelo-3 trial for zelenectide in NECTIN4-amplified breast cancer and the Phase 1/2 Duravelo-4 trial for zelenectide in NECTIN4-amplified non-small cell lung cancer. 30% workforce reduction

@BlueWinterMgmt I don't invest in companies? It is not my favorite company -- and I do not have a favorite company. I like that someone made their ticker "G protein coupled receptor." Because I like clever tickers.

🚨 Here is the full 40 minutes of my crew and I exposing California fraud, Minnesota was big but California is even bigger... We uncovered over $170,000,000 in fraud as these fraudsters live in luxury with no consequences. Like it and share it, the fraud must STOP. We ALL work way too hard and pay too much in taxes for this to be happening. These fraudsters have been able to defraud American taxpayers for years without any pushback from the public and politicians. It is time to EXPOSE IT ALL and end America's fraud crisis.

@daphnezohar @BiotechCH spent most of 2025 being told by one of our top bosses we were too negative. as if it were our choice and not the reality of what was happening at federal health agencies.

@emilyakopp @daphnezohar There are dozens. Hundreds maybe! Take a look at articles around Wave, Sarepta, Recursion, and others.